Arbaclofen placarbil

Arbaclofen placarbil
Clinical data
Pregnancy; category	N/A;
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid;
CAS Number	847353-30-4;
PubChem CID	11281011;
ChemSpider	9456008;
KEGG	D08861 ;
ChEMBL	CHEMBL2107312 ;
ECHA InfoCard	100.221.150
Chemical and physical data
Formula	C19H26ClNO6
Molar mass	399.86 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl;
	InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1; Key:JXTAALBWJQJLGN-KSSFIOAISA-N;

Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.^[1]

It is being developed as an addiction medicine to treat alcoholism. ^[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Results-1] ttp://investor.xenoport.com/releasedetail.cfm?ReleaseID=765868

[2] ttps://inews.co.uk/essentials/news/business/pill-replaces-alcohol-aims-end-middle-class-drinking-epidemic/

Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Niperotidine Nizatidine Ranitidine^# Roxatidine
Prostaglandins (E)/analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Azeloprazole Dexlansoprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole^# Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Linaprazan Revaprazan Soraprazan Vonoprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline
See also: Helicobacter pylori* eradication protocols*
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Clinical data

Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
CAS Number	847353-30-4
PubChem CID	11281011
ChemSpider	9456008
KEGG	D08861^Y
ChEMBL	CHEMBL2107312^Y
ECHA InfoCard	100.221.150
Chemical and physical data
Formula	C₁₉H₂₆ClNO₆
Molar mass	399.86 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
InChI InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1 Key:JXTAALBWJQJLGN-KSSFIOAISA-N

Arbaclofen placarbil

See also

References